Bortezomib (BTZ) and dasatinib (DA) are two substantial anti-cancer agents with side effects on the human body. In this research, we fabricated a novel electrochemical sensor modified by CuFe2O4/ SmVO4 nanocomposite and 1-ethyl-3-methylimidazolium chloride (1E3MC) as an ionic liquid (IL) ( CuFe2O4/SmVO4/IL/CPE) for coinciding investigation of BTZ and DA for the first time. The CuFe2O4/ SmVO4 synthesized were determined and certified through field-emission scanning electron microscopy (FE-SEM), energy diffraction X-ray (EDX), and X-ray diffraction (XRD). The capability of the sensor was investigated by different electrochemical techniques such as cyclic voltammetry (CV), chronoamperometry (CHA), differential pulse voltammetry (DPV), and electrochemical impedance spectroscopy (EIS). The attained data showed that the oxidation signal of bortezomib and dasatinib promoted as an innovative electrochemical sensor. After optimization of the conditions using this sensor at pH 7.0, the oxidation signal of bortezomib and dasatinib showed to be linear with drug concentrations in the range of 0.09–90 μM and 100–500 μM with a detection limit of 5.4 nM and 7.0 μM, respectively, using differential pulse voltammetry method. The values of D and electro-transfer coefficient (α) achieved 2.5 × 10− 5 cm2 s− 1 and 0.99, respectively. The proposed electrochemical sensor exhibited acceptable selectivity and sensitivity for simultaneous detection of bortezomib and dasatinib in pharmaceutical and biological samples.

It is well understood that developing new drugs is one of the highest value-added businesses in a country; however, the current governments' spending in pharmaceutical research and development(R&D) is minimal in Korea. This paper suggests that different governmental bodies should take in charge of different stages of the R&D process in order to maximize the use of limited government research funding. First, during the initial phase of the drug development, including clinical trials, the Ministry of Education, Science and Technology is the most appropriate governmental organization to support the research. For later procedures such as supporting the industries for exporting developed drugs, legislative approvals, and building infrastructure for future clinical trials should be supported by the Ministry of Knowledge and Economy and the Ministry of Health and Welfare along with the Korea Food and Drug Administration(KFDA). The KFDA, which is the main governmental agency approving newly developed drugs in the market, will need to take a crucial responsibility in the initial phase of the pharmaceutical R&D by guiding the industries with timely and proper information. As a first step, it is recommended to set up and operate a center for supporting new drugs, so that the industries can facilitate the development of marketable drugs which meet customers' needs. Later, in order to expedite the process of exporting and getting approvals of the newly developed drugs from foreign countries, it is necessary to develop new approval system, which includes introduction of the Good Manufacturing Practice (GMP), mandatory validation system, and education program for supporting expertise. Lastly, the KFDA needs to take an active role in developing Korean pharmaceutical industries by communicating with other foreign governments with regards to the globalization of the Korean pharmaceutical industries. For example, as a follow up after the Free Trade Agreement(FTA), active discussion on GLP of Mutual Recognition Agreement(MRA) with the United States of America, should be seriously considered.

The copper oxide nano powders were synthesized by levitational gas condensation (LGC) method, and were applied to catalyst to fabricate 3,4-dihydropyrimidin-2-(1H)-one. Processes of adsorption of Biginelli reaction reagents on the copper nanooxide surface were studied by IR-spectroscopy. It was shown that benzaldehyde coordination, acetoacetic ether on the oxide surface is carried out with participation of carbonyl fragments, urea by N-H bonds which affects positively on the reagents reactivity.